EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association Between Pruritus and Healthcare Utilization and Costs Among Individuals With Primary Biliary Cholangitis

Robert G. Gish, Michel H. Mendler, Edward A. Mena, Chong Kim, C. Fiorella Murillo Perez, Yi Pan, Lauren A. Do, Mihail Samnaliev, Maria Agapova

Liver International Communications · 2026-06 · 7 (2)

DOI: 10.1002/lci2.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International Communications, online erschienen am 09.05.2026. Verfasst von Robert G. Gish und 8 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Pruritus is a debilitating, under‐prioritized symptom of primary biliary cholangitis (PBC). This study assessed its impact on healthcare resource utilization (HCRU) and costs in the US.

Methods

A retrospective cohort study of individuals with PBC was conducted using Komodo's claims and laboratory data between September 1, 2017 and September 30, 2023. Individuals' index date was a randomly selected medical event with (cases) or without pruritus diagnosis (controls) after initial PBC diagnosis. Participants were ≥ 18 years old with continuous insurance eligibility for ≥ 12 months before and after their index, excluding those on obeticholic acid during baseline. Negative binomial models estimated HCRU rate ratios, and linear models estimated incremental all‐cause total costs (2024 USD) associated with pruritus, adjusting for baseline demographics and clinical characteristics.

Results

10 077 patients with PBC and pruritus and 41 957 controls (PBC only) were identified. Regression‐adjusted HCRU rate ratios for pruritus vs. controls were 1.69 (inpatient), 1.36 (outpatient), 1.65 (emergency), and 1.44 (prescription counts) and one‐year adjusted healthcare costs averaged $39 949 for pruritus and $25 695 for controls, with an incremental cost of $14 254 (all p < 0.001). In sensitivity analyses, incremental costs ranged from $11 495 (using a broader definition of pruritus diagnosis or treatment) to $27 669 (using a stricter definition of pruritus diagnosis and treatment within ±90 days of diagnosis; both p < 0.001).

Conclusion

Pruritus significantly increases HCRU and costs in PBC, highlighting the economic argument for improved management. Further research should assess the effectiveness of novel PBC therapies in slowing liver disease progression and mitigating pruritus symptoms concomitantly.

Förderung

  • Gilead Sciences

Zitieren

APA

Gish, R. G., Mendler, M. H., Mena, E. A., Kim, C., Perez, C. F. M., Pan, Y., Do, L. A., Samnaliev, M., & Agapova, M. (2026). Association Between Pruritus and Healthcare Utilization and Costs Among Individuals With Primary Biliary Cholangitis. Liver International Communications, 7(2). https://doi.org/10.1002/lci2.70044

Vancouver

Gish RG, Mendler MH, Mena EA, Kim C, Perez CFM, Pan Y, et al. Association Between Pruritus and Healthcare Utilization and Costs Among Individuals With Primary Biliary Cholangitis. Liver International Communications. 2026;7(2). doi:10.1002/lci2.70044

BibTeX
@article{Gish2026,
  author = {Gish, Robert G. and Mendler, Michel H. and Mena, Edward A. and Kim, Chong and Perez, C. Fiorella Murillo and Pan, Yi and Do, Lauren A. and Samnaliev, Mihail and Agapova, Maria},
  title = {Association Between Pruritus and Healthcare Utilization and Costs Among Individuals With Primary Biliary Cholangitis},
  journal = {Liver International Communications},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.1002/lci2.70044}
}
Kostenlos starten →